Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321788270> ?p ?o ?g. }
- W4321788270 endingPage "17" @default.
- W4321788270 startingPage "17" @default.
- W4321788270 abstract "Mutation(s) in the spike protein is the major characteristic trait of newly emerged SARS-CoV-2 variants such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Delta-plus. Omicron (B.1.1.529) is the latest addition and it has been characterized by high transmissibility and the ability to escape host immunity. Recently developed vaccines and repurposed drugs exert limited action on Omicron strains and hence new therapeutics are immediately needed. Herein, we have explored the efficiency of twelve therapeutic monoclonal antibodies (mAbs) targeting the RBD region of the spike glycoprotein against all the Omicron variants bearing a mutation in spike protein through molecular docking and molecular dynamics simulation. Our in silico evidence reveals that adintivimab, beludivimab, and regadanivimab are the most potent mAbs to form strong biophysical interactions and neutralize most of the Omicron variants. Considering the efficacy of mAbs, we incorporated CDRH3 of beludavimab within the framework of adintrevimab, which displayed a more intense binding affinity towards all of the Omicron variants viz. BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Furthermore, the cDNA of chimeric mAb was cloned in silico within pET30ax for recombinant production. In conclusion, the present study represents the candidature of human mAbs (beludavimab and adintrevimab) and the therapeutic potential of designed chimeric mAb for treating Omicron-infected patients." @default.
- W4321788270 created "2023-02-25" @default.
- W4321788270 creator A5032807204 @default.
- W4321788270 creator A5042962895 @default.
- W4321788270 creator A5086147416 @default.
- W4321788270 creator A5086935965 @default.
- W4321788270 date "2023-02-23" @default.
- W4321788270 modified "2023-10-01" @default.
- W4321788270 title "Comparative Binding Ability of Human Monoclonal Antibodies against Omicron Variants of SARS-CoV-2: An In Silico Investigation" @default.
- W4321788270 cites W1987474460 @default.
- W4321788270 cites W2071486470 @default.
- W4321788270 cites W2102993309 @default.
- W4321788270 cites W2113623846 @default.
- W4321788270 cites W2114698599 @default.
- W4321788270 cites W2121895929 @default.
- W4321788270 cites W2154019529 @default.
- W4321788270 cites W2172241314 @default.
- W4321788270 cites W2344483747 @default.
- W4321788270 cites W2512372054 @default.
- W4321788270 cites W2792323544 @default.
- W4321788270 cites W2794789522 @default.
- W4321788270 cites W2804822363 @default.
- W4321788270 cites W2885319161 @default.
- W4321788270 cites W2891848970 @default.
- W4321788270 cites W2892113269 @default.
- W4321788270 cites W2905570097 @default.
- W4321788270 cites W2913847447 @default.
- W4321788270 cites W2982586377 @default.
- W4321788270 cites W2998920750 @default.
- W4321788270 cites W3006645647 @default.
- W4321788270 cites W3012320055 @default.
- W4321788270 cites W3013232761 @default.
- W4321788270 cites W3021577931 @default.
- W4321788270 cites W3033653399 @default.
- W4321788270 cites W3046338595 @default.
- W4321788270 cites W3046463683 @default.
- W4321788270 cites W3082246640 @default.
- W4321788270 cites W3082738962 @default.
- W4321788270 cites W3091808735 @default.
- W4321788270 cites W3118790862 @default.
- W4321788270 cites W3125712166 @default.
- W4321788270 cites W3133980772 @default.
- W4321788270 cites W3139903895 @default.
- W4321788270 cites W3155123963 @default.
- W4321788270 cites W3159257193 @default.
- W4321788270 cites W3160305813 @default.
- W4321788270 cites W3165790948 @default.
- W4321788270 cites W4200063552 @default.
- W4321788270 cites W4200180765 @default.
- W4321788270 cites W4200425120 @default.
- W4321788270 cites W4200520868 @default.
- W4321788270 cites W4205647504 @default.
- W4321788270 cites W4206135665 @default.
- W4321788270 cites W4206185298 @default.
- W4321788270 cites W4206365084 @default.
- W4321788270 cites W4206634366 @default.
- W4321788270 cites W4206644256 @default.
- W4321788270 cites W4206737621 @default.
- W4321788270 cites W4206898072 @default.
- W4321788270 cites W4210282471 @default.
- W4321788270 cites W4210878661 @default.
- W4321788270 cites W4214535681 @default.
- W4321788270 cites W4220807057 @default.
- W4321788270 cites W4221073688 @default.
- W4321788270 cites W4221103003 @default.
- W4321788270 cites W4221116249 @default.
- W4321788270 cites W4223499046 @default.
- W4321788270 cites W4223541187 @default.
- W4321788270 cites W4225112745 @default.
- W4321788270 cites W4225156805 @default.
- W4321788270 cites W4226108318 @default.
- W4321788270 cites W4253565130 @default.
- W4321788270 cites W4280578293 @default.
- W4321788270 cites W4281703093 @default.
- W4321788270 cites W4281939105 @default.
- W4321788270 cites W4283802705 @default.
- W4321788270 cites W4285808313 @default.
- W4321788270 cites W4286009139 @default.
- W4321788270 cites W4288425376 @default.
- W4321788270 cites W4292295463 @default.
- W4321788270 cites W4294733888 @default.
- W4321788270 cites W4306249182 @default.
- W4321788270 cites W4309655532 @default.
- W4321788270 cites W4318938794 @default.
- W4321788270 doi "https://doi.org/10.3390/antib12010017" @default.
- W4321788270 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36975364" @default.
- W4321788270 hasPublicationYear "2023" @default.
- W4321788270 type Work @default.
- W4321788270 citedByCount "3" @default.
- W4321788270 countsByYear W43217882702023 @default.
- W4321788270 crossrefType "journal-article" @default.
- W4321788270 hasAuthorship W4321788270A5032807204 @default.
- W4321788270 hasAuthorship W4321788270A5042962895 @default.
- W4321788270 hasAuthorship W4321788270A5086147416 @default.
- W4321788270 hasAuthorship W4321788270A5086935965 @default.
- W4321788270 hasBestOaLocation W43217882701 @default.
- W4321788270 hasConcept C104317684 @default.
- W4321788270 hasConcept C153911025 @default.